Navigation Links
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
Date:8/5/2008

MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies Inc. (MicroDose) today announced that the first clinical milestone in its collaboration with Merck & Co., Inc., through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for MicroDose's dry powder inhaler (DPI) technology announced in March 2008. This milestone signals the initiation by Merck of a Phase I clinical study of an investigational compound using the MicroDose DPI technology.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070803/NYF045LOGO )

As previously announced, Merck will fund development and commercialization of products that employ MicroDose's DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

"MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months" commented David Byron, Vice President of Research and Development, MicroDose. "Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration."

About the MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical trials. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries.

In addition to the collaboration with Merck, MicroDose's other partnerships include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose's QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the U.S. Department of Defense, in collaboration with the University of Pittsburgh. MicroDose has ongoing feasibility programs with other major pharmaceutical companies and is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap(TM) technology, in the

areas of diabetes, hypertension and hyperlipidemia. For more information visit us at http://www.microdose-tech.com


'/>"/>
SOURCE MicroDose Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
2. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
3. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
6. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
7. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
8. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
9. Senesco Technologies Initiates Preclinical Studies for Cancer Target
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/8/2017)...   Second-quarter 2017 ... loss per share from continuing operations ... 16 percent to $110 million ... to $161 million Second-quarter ... operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology:
(Date:8/24/2017)... Raton (PRWEB) , ... August 24, 2017 , ... ... dietary supplements that help people improve all aspects of their health and wellness, ... States. , The step represents a component of Natural Subsistence’s aggressive marketing strategy ...
(Date:8/24/2017)... ... August 24, 2017 , ... Indosoft Inc. announces the ... of contact center application development experience. It represents a complete redesign of ... Indosoft designed Q-Suite NG for simple integration. A full set of APIs allows ...
(Date:8/23/2017)... ... 23, 2017 , ... Jachimowicz Law Group is excited to announce ... 115. The office is located between Schiele and Pershing avenues, with convenient parking for ... can still call the office at 408-246-5500. , Jachimowicz Law Group has ...
(Date:8/23/2017)... ... August 23, 2017 , ... Earlier this month, the Workgroup for Electronic ... IT to create efficiencies in healthcare information exchange and a trusted advisor to the ... which featured keynote addresses by Donald W. Rucker, MD, head of the Office ...
(Date:8/23/2017)... ... 2017 , ... Nightingale College continues the semiannual Give Back Day tradition for ... College dedicates to serving and volunteering for organizations that provide indispensable resources to the ... that need a little extra help. , The College’s Give Back Day initiative ...
Breaking Medicine News(10 mins):